Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Oncol Pract ; 6(6): e21-6, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21358946

ABSTRACT

Multidisciplinary care refers to a practice in which physicians from multiple specialties attend to the same patient population. There are many advantages to the model, including reduced time to treatment, coordinated treatment plans, increased patient and physician satisfaction, and increased enrollment onto clinical trials. At Central Dupage Hospital, multidisciplinary clinics have been instituted in lung and gynecologic cancer. We describe the structure and operation of each clinic and highlight their considerable success in improving patient care.

2.
Blood ; 99(6): 2255-8, 2002 Mar 15.
Article in English | MEDLINE | ID: mdl-11877308

ABSTRACT

Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m(2) intravenously daily for 5 days) and melphalan (70 mg/m(2) intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Primary Myelofibrosis/drug therapy , Transplantation Conditioning/methods , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/toxicity , Bone Marrow/drug effects , Bone Marrow/pathology , Follow-Up Studies , Graft Survival/drug effects , Histocompatibility Testing , Humans , Male , Melphalan/administration & dosage , Melphalan/toxicity , Middle Aged , Primary Myelofibrosis/complications , Splenomegaly/drug therapy , Transplantation Chimera , Transplantation Conditioning/standards , Transplantation, Homologous/methods , Treatment Outcome , Vidarabine/administration & dosage , Vidarabine/analogs & derivatives , Vidarabine/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...